Results 161 to 170 of about 10,517,468 (269)
T‐lymphoblastic lymphoma relapsing as acute myeloid leukaemia [PDF]
G, Shenton, A, Thomas
openaire +2 more sources
ABSTRACT Cardiovascular adverse events (CVAEs) associated with bispecific T‐cell engaging antibodies (BsAbs) have not been systematically investigated across approved agents. In this disproportionality analysis of FAERS (December 2014–September 2025), reports listing BsAbs as the primary suspected drug (n = 7647) were compared with all other drugs in ...
Malak Munir +9 more
wiley +1 more source
Diagnosis-to-Treatment Interval Reflects Clinical Urgency and Disease Burden in T-Lymphoblastic Lymphoma: A Multicenter Cohort Study. [PDF]
Chai J +10 more
europepmc +1 more source
Model‐informed drug development is increasingly used to support chimeric antigen receptor (CAR)‐T‐cell therapy programs. However, most population pharmacokinetic (PK) CAR‐T‐cell models available in literature are variations of an empirical piecewise‐linear model, which accurately describes the observed data but lacks a mechanistic foundation.
Anna M. Mc Laughlin +4 more
wiley +1 more source
Pituitary T-lymphoblastic lymphoma combined with pituitary adenoma: a rare case report. [PDF]
Chen X, Cheng L, Li Z, Li G.
europepmc +1 more source
Abstract UKALL14 (NCT01085617) T‐cell arm was a phase 3, randomized‐controlled trial. Adults aged 25–65 years were randomized 1:1 at entry to receive standard of care (SOC) or SOC + nelarabine 1.5 g/m2 (Days 1, 3, and 5) to be administered following second induction. The primary end‐point was event‐free survival (EFS).
Clare J. Rowntree +14 more
wiley +1 more source
Long-term outcomes after allogeneic versus autologous haematopoietic stem cell transplantation for T-lymphoblastic lymphoma. [PDF]
Cheng Q +9 more
europepmc +1 more source
Acute myeloid leukemia with T lymphoblastic lymphoma: a case report and literature review. [PDF]
Gao Y +7 more
europepmc +1 more source
ABSTRACT The standard for assessing and recording the extent of the tumour, a necessity for most malignancies, is the Tumour Node Metastases (TNM) classification. The Union for International Cancer Control (UICC) TNM committee has defined this since the early 1950s.
James D. Brierley +8 more
wiley +1 more source

